Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDQ443 dose escalation and expansion in KRAS G12C-mutant advanced solid tumors
2023-508073-87-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of opnurasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (5 arms), sponsored by Novartis. Primary endpoints: Dose Escalation: Safety (DLTs and AEs), Dose Escalation: Tolerability and 5 more. Planned start Apr 2021; status: authorised.
02
Drugs
opnurasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-508073-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508073-87-00.